Role of Janus Kinase 3 in Mucosal Differentiation and Predisposition to Colitis

Jayshree Mishra, Raj K. Verma, Gianfranco Alpini, Fanyin Meng, and Narendra Kumar

From the Department of Pharmaceutical Sciences, College of Pharmacy, Texas A&M University System Health Science Center, Kingsville, Texas 78363 and the Central Texas Veterans Health Care System, Scott and White Digestive Disease Research Center, and Texas A&M Health Science Center College of Medicine, Temple, Texas 76504

Background: Jak3 is a tyrosine kinase, and its role in mucosal differentiation is not known.

Results: Jak3, expressed in colonic mucosa, was essential for differentiation, goblet cell surface localization, muc2 expression, and epithelial barrier functions.

Conclusion: Jak3 plays a protective role against predisposition to colitis by promoting mucosal differentiation.

Significance: Understanding mucosal functions of Jak3 has important implications for patients with inflammatory bowel disease.

Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase expressed in both hematopoietic and nonhematopoietic cells. Previously, we characterized the functions of Jak3 in cytoskeletal remodeling, epithelial wound healing, and mucosal homeostasis. However, the role of Jak3 in mucosal differentiation and inflammatory bowel disease was not known. In this report, we characterize the role of Jak3 in mucosal differentiation, basal colonic inflammation, and predisposition toward colitis. Using the Jak3 knock-out (KO) mouse model, we show that Jak3 is expressed in colonic mucosa of mice, and the loss of mucosal expression of Jak3 resulted in reduced expression of differentiation markers for the cells of both enterocytic and secretory lineages. Jak3 KO mice showed reduced expression of colonic villin, carbonic anhydrase, secretory mucin muc2, and increased basal colonic inflammation reflected by increased levels of proinflammatory cytokines IL-6 and IL-17A in colon along with increased colonic myeloperoxidase activity. The inflammations in KO mice were associated with shortening of colon length, decreased cecum length, decreased crypt heights, and increased severity toward dextran sulfate sodium-induced colitis. In differentiated human colonic epithelial cells, Jak3 redistributed to basolateral surfaces and interacted with adherens junction (AJ) protein β-catenin. Jak3 expression in these cells was essential for AJ localization of β-catenin and maintenance of epithelial barrier functions. Collectively, these results demonstrate the essential role of Jak3 in the colon where it facilitated mucosal differentiation by promoting the expression of differentiation markers and enhanced epithelial barrier functions through AJ localization of β-catenin.

Differentiation in the gastrointestinal tract is a highly organized process by which proliferative compartments of the intestinal epithelium (known as crypt) contribute to the renewal of intestinal epithelial mucosa. A small number of cells at the bottom of the crypt (known as stem cells) slowly proliferate to give a transient population of progenitor cells that rapidly divide at the same time migrating toward the lumen of the intestine. Depending on the extracellular cues and cytokine profiles, progenitor cells become committed toward one of the three different lineages as follows: absorptive cells displaying a brush border, goblet cells containing mucous granules, and enteroendocrine cells containing dense secretory granules (1). The integrity of epithelial barriers comprising these differentiated cells was impaired and compromised in the course of various intestinal disorders such as inflammatory bowel disease (IBD), celiac disease, and intestinal infection (2). Intestinal differentiation is essential for the protection of the mucosal surfaces. Ulcerative colitis is associated with defects in differentiation with reduced numbers of differentiated cells and reduced thickness of the mucous layer overlaying the colonic mucosa (3, 4). Although different genes have been implicated in IBD (5), the role of epithelial Jak3 in ulcerative colitis is not known.

Janus kinases (Jaks) are a family of nonreceptor tyrosine kinase with four members as follows: Jak1, Jak2, Jak3, and Tyk2. Like other members, Jak3 mediates signals initiated by cytokines through interactions with receptors for IL-2, IL-5, IL-7, IL-9, and IL-15 via the common γ chain of these receptors (6). Different studies have shown that Jak3 is widely expressed in different organs, including intestine and kidney of both humans and mice (6, 7). Previous studies with IL-2Rγ-null mice showed that it developed spontaneous IBD symptoms (8). Moreover, abnormal activation of Jak3 was associated with human hematological and epithelial malignancies (9–11), indicating that a

* This work was supported, in whole or in part, by National Institutes of Health Grant DK081661 (to N. K.). This work was also supported by Crohn’s and Colitis Foundation of America Grant CCFA 2188 and the Dr. Nicholas C. Hightower Centennial Chair of Gastroenterology Endowment from the Scott and White Hospital (to G. A.).

† This article contains supplemental Figs. S1 and S2.

1 To whom correspondence should be addressed: College of Pharmacy, Texas A&M University HSC, 1010 West Ave., B MSC 131, Kingsville, TX 78363. Fax: 361-593-4303; E-mail: nkumar@tamhsc.edu.

2 The abbreviations used are: IBD, inflammatory bowel disease; AJ, adherens junction; TEER, trans-epithelial electrical resistance; IEC, intestinal epithelial cells; IP, immunoprecipitation; IB, immunoblotting; Jak3, Janus kinase 3; PLE, protein-losing enteropathy; MPO, myeloperoxidase; DSS, dextran sulfate sodium; RFP, red fluorescence protein; IFM, immunofluorescence microscopy.
Lack of Jak3 Expression Predisposes to Colitis

tight balance in its activity was not only essential for normal hematopoietic development but also for epithelial functions. Recently, we reported the essential functions of Jak3 in cytoskeletal remodeling and epithelial wound repair (12), through its interactions with cytoskeletal proteins (13). Although we also reported that Jak3 played an important role in mucosal homeostasis through its interactions with adapter protein p52ShcA (14), the in vivo mucosal functions of Jak3 are less understood. In this study, we characterize the role of Jak3 on mucosal differentiation, colonic inflammation, and structural changes in mucosal surfaces of colon, and we demonstrate the mechanism of Jak3-mediated mucosal differentiation, where Jak3 regulated the expression of differentiation markers, formation of mucus in mice, and facilitated barrier functions through its interactions and adherens junction (AJ) localization of β-catenin in human intestinal epithelial cells (IEC).

EXPERIMENTAL PROCEDURES

Materials—Materials were obtained from the following sources: HT-29 CL-19A, a permanently differentiated homogeneous clone derived from human colonic epithelial cells HT-29, was a gift from Dr. A. P. Naren, University of Tennessee Health Science Center at Memphis, TN (15); HEK293T cells, Jak3-shRNA, and Shc-shRNA (Open Biosystems); doxycycline (Sigma); dextran sulfate sodium (DSS) 40,000 kDa (United States Biochemical); hematoxylin, eosin, and xylene (VWR Scientific); Alcian blue and tetramethylbenzidine substrate kit (Thermo Scientific). Antibodies and kits were obtained from the following sources: pY20 (MP Biomedicals); p(Y142) β-catenin (Abcam®); Jak3, villin, IgG, β-catenin, β-actin, and carbonic anhydrase (Santa Cruz Biotechnology); muc2 (Novus Biologicals); α1-antitrypsin (Sigma); MultiAnalyte cytokine assay kit (Qiagen); 3,3′-diaminobenzidine substrate kit (Vector Laboratories); and Pierce® BCA protein assay kit (Thermo Scientific).

Animals—Six- to 8-week-old C57BL/6 mice (WT) or C57BL/6-background jak3−/− mice (KO) were purchased from The Jackson Laboratory. This study adhered to the institutional guidelines of Texas A&M University Institutional Animal Care and Use Committee.

Induction of Colitis by DSS—Male WT and KO mice weighing 20–25 g were used for the experiments. The animals were housed in a specific pathogen-free facility in individually ventilated cages. Acute colitis was induced by feeding 2.5% DSS in drinking water over a period of 9 days. This procedure is known to induce colonic epithelial injury (16, 17). Animals were provided unlimited access to food and water throughout the experiment (ad libitum). Body weights of mice were measured daily. The mice that lost ≥20% of initial body weight were euthanized, and all the data shown are based on this end point. Following treatment, the distal colon and serum were sampled for analysis. Images were taken by a Nikon camera. Quantitation of colon length, colon to body weight ratio, length of cecum, and crypt lengths were calculated using NIS element imaging software (Nikon®).

Disease Score in Colitis—Progression of colitis was evaluated daily by measuring the body weight loss, stool consistency, and presence of fecal blood. An earlier validated clinical disease activity index was calculated according to the following parameters: stool consistency (0–4), the presence or absence of fecal blood (0–4), and body weight loss (0–4). The maximum possible score taken was 12 (18, 19).

Tissue Staining and Histological Damage Scoring for Colitis—The distal colons of WT and KO mice with or without treatment were dissected out and cut into small pieces (3–4 mm long). The fresh tissues were placed in a mold containing OCT (Sakura Inc.) solution and frozen. Tissue cross-sections (5–10 μm thick) were stained with hematoxylin and eosin (H&E) using standard protocol. The mean degree of acute colitis in the colon was calculated from observation of 25 different fields of H&E-stained sections of colon from each animal (20). The degree of colitis was evaluated by the following histopathological scoring system. (a) Areas of activity (erosions and inflammation), possible dysplasia, crypt distortion, and plasmatic infiltrates were considered indicative of colonic inflammation. Two independent parameters were measured as reported by others (21) as follows: the extent of inflammation (0, none; 1, slight; 2, moderate; 3, severe; 4, massive) and the extent of crypt damage (0, none; 1, the basal one-third portion damaged; 2, the basal two-thirds portion damaged; 3, the entire crypt damaged but the surface epithelium intact; 4, the entire crypt and epithelium lost). The maximum possible score was 6. H&E-stained slides were visualized using a Nikon microscope, and the images were processed using NIS element software (Nikon®) to calculate crypt lengths and cecum lengths.

Myeloperoxidase (MPO) Assay—MPO activities were measured by colorimetric assay and used as an index of inflammation (22). Briefly, tissue samples from colon were homogenized in ice-cold buffer (50 mM K2HPO4 and 50 mM KH2PO4, pH 6.0) containing 0.5% hexadecytrimethyl ammonium bromide (Sigma). The homogenates were sonicated, freeze-thawed three times, and centrifuged. Supernatants (25 μl) were used for MPO activities. The enzymatic reactions were carried out by adding 25 μl of 1.6 mM tetramethylbenzidine in 80 mM sodium phosphate (NaPO4). The reactions were stopped by adding 100 μl of 0.3 mM H2O2. MPO activity was measured spectrophotometrically at 650 nm, and results were expressed as optical density per mg of tissue.

Immunofluorescence Microscopy (IFM) and Immunohistochemistry—For IFM, OCT mold-embedded tissue sections were air-dried for 20 min at RT, fixed using 4% paraformaldehyde, and blocked using 5% BSA in PBS for 30 min. Sections were then rinsed twice with PBS and mounted using Vectashield (Vector Laboratories). For all negative controls, primary antibodies were replaced with a control nonimmune IgG at the same concentrations. IFM for HT-29 CL-19A cells transduced with RFP-tagged Jak3 shRNA were done as reported previously (14). The immunostained slides were visualized using C1-plus Nikon laser scanning confocal microscope, and the images were processed using NIS element software (Nikon®). All experiments were conducted at least in triplicate, and representative images were shown. For immunohistochemistry, the aforementioned sections from frozen tissue
block were fixed with pre-cooled acetone at –20 °C. Endogenous peroxidase activity was inactivated by incubating the tissue with 0.3% H2O2 for 10 min. Nonspecific binding was blocked by 45 min of incubation with 10% fetal bovine serum prior to incubation with primary antibodies. The sections were then incubated with biotinylated secondary antibody followed by staining with Vectastain ABC kit (Vector Laboratories). The reaction was visualized using the 3,3′-diaminobenzidine substrate.

**Alcian Blue Staining**—The aforementioned tissues sections were air-dried and fixed with anhydrous alcohol followed by staining with Alcian blue for 30 min and counter-staining with the diluted eosin. Tissue sections were dehydrated in anhydrous alcohol and then immersed in clearing reagent followed by mounting for visualization.

**Cytokine and α1-Antitrypsin Assays**—IL-6 and IL-17a were determined in the sera of blood serum using BCA reagent. Serum albumin was measured using a microplate reader (Awareness Technologies). The reaction was visualized using the 3,3′-diaminobenzidine substrate.

Serum Total Protein and Albumin Analysis—Total serum protein from WT and KO mice was measured by densitometry and by the bromcresol purple color of blood serum using BCA reagent. Serum albumin was determined in the sera of blood serum using BCA reagent. Serum albumin was measured using MolecularImager (ChemiDoc Lab™ XRS, Bio-Rad) equipped with Image Lab™ software.

**Immunoprecipitation (IP), Western Blot (IB), and Dot Blot Analysis**—The frozen colon tissue samples from WT and KO mice were divided into equal volumes of blood serum using BCA reagent. Serum albumin was determined by densitometry and by the bromcresol purple method as reported (23, 24). Densitometric analysis of PAGE-separated proteins were done using MolecularImager (ChemiDoc Lab™ XRS, Bio-Rad) equipped with Image Lab™ software.

**Measurement of Trans-epithelial Electrical Resistance (TEER)**—TEER was measured using Millicell electrical resistance system (Millipore) as reported (14, 26) and expressed as ohms/cm², where ohm is the observed value of resistance, and cm² is the surface area of the membrane. The background resistance of the trans-well membrane (~30 ohms/cm²) was subtracted from the observed resistance values.

**Data Analysis**—Differences in the survival rates were evaluated by the log rank test. All data are presented as mean ± S.E. and analyzed with the univariate analysis of variance using Origin® software version 9.2. Differences in the parametric data were evaluated by the Student’s t test. Significance in all tests was set at a 95% or greater confidence level.

**RESULTS**

Knock-out of jak3 Gene Leads to Increased Severity toward DSS-induced Colitis—The DSS-induced colitis in the murine model is commonly used to address the pathogenesis of IBD (27). Previously, we reported the essential roles of Jak3 in mucosal wound healing and homeostasis (12–14); here, we determined the effects of Jak3 KO in DSS-induced colitis. Eight-week-old WT and c57/bl jak3−/− mice were given 2.5% (w/v) DSS in drinking water for 9 days using the previously described model (28, 29), and the time course of body weight change and parameters for inflammation were determined to measure the induction and severity of colitis. Although the body weight was slightly increased in untreated Jak3 KO mice compared with WT, the body weight decreased progressively in both WT and KO mice following DSS treatment, and the KO mice started showing the signs of illness and severity much earlier than the WT. There was significant weight loss and mortality following the DSS treatment in Jak3 KO group compared with the wild type (Fig. 1A). The decreased survival in Jak3 KO mice started on day 8 (32% versus 8% in WT p < 0.08) and worsened on day 9 (74% versus 35% in WT p < 0.05). The effect of DSS treatment on the time course of weight loss showed that although WT mice lost about 10–14% of initial weight following 9 days of DSS treatment, Jak3 KO mice started losing weight as early as 5 days post-treatment, and about 20–26% of initial weight was lost at 9 days of DSS treatment, which precluded further observation of the mice. The time course of disease activity index as calculated by weight loss, stool consistency, and presence of fecal blood showed that it was significantly higher in KO mice compared with WT from days 6 to 9 (Fig. 1B). During this treatment period, inflammation was enhanced in the KO mouse group, as indicated by rises in the extent of diarrhea and rectal bleeding. Because of the substantial mortality after 9 days of DSS treatment in Jak3 KO group, we used this time point to further confirm colonic inflammation by MPO activity and histology. Measurement of MPO activity as a measure of inflammation showed that it increased by 1.5-fold in KO mice compared with
the WT (Fig. 1C). H&E-stained day 9 colon sections of DSS-treated mice showed severe lesions throughout the mucosa, alteration of epithelial structure, high levels of neutrophil and lymphocyte infiltration into the mucosal and submucosal areas, and loss of crypts, whereas all of these were higher in KO mice (Fig. 1D). These observed alterations were combined to obtain histological scores (Fig. 1E), which were 3-fold higher in KO mice compared with WT. To confirm further, we measured the colon to body weight ratios in these two groups. These ratios were significantly decreased in KO mice, again indicating a higher colonic inflammation in Jak3 KO mice (Fig. 1F). Taken together, these results indicated that KO of Jak3 resulted in increased severity toward DSS-induced colitis in mice.

Jak3 KO Leads to Increased Basal Colonic Inflammation—Because Jak3 KO mice showed increased severity toward DSS-induced colitis and previously we reported that Jak3 plays a role in different mucosal functions (12–14), we determined whether the KO of Jak3 had an impact on colon and colonic mucosa. As shown in Fig. 2A and B, KO of Jak3 resulted in significant shortening of average colon lengths that were about 26% shorter than their WT counterpart. Additionally, the KO mice also had significantly shorter ceca (Fig. 2C). Because Jak3 KO mice had shorter colons, we determined whether colonic mucosae of these mice were affected. As shown in representative H&E sections in Fig. 2D (×40 and ×100), the epithelial architecture toward the colonic lumen was perturbed in KO mice with interruptions in epithelial lining compared with the

FIGURE 1. Knock-out of jak3 gene leads to increased severity toward DSS-induced colitis. A, time course of body weight change during DSS-induced colitis. WT and jak3−/− (KO) mice (n = 6, each group) were treated with water or 2.5% DSS for the indicated periods, and the percent change in body weight was plotted versus days of treatment. B, time course of the disease activity index during DSS treatment. The disease activity index was determined in WT and KO mice as described under “Experimental Procedures” and plotted versus days of treatment. C, MPO in colonic mucosal scrapings. MPO activity was determined as described under “Experimental Procedures.” D and E, histological analysis of DSS-induced colitis. Fresh frozen colon sections from WT and KO mice were stained with H&E; representative sections are shown with indicated magnifications from each group (n = 6) (D). E, colonic H&E sections from each animal under D were scored in a blinded fashion using protocol described under “Experimental Procedures.” F, colon to body weight ratios of DSS-treated WT (control) and Jak3 KO mice were calculated, and values are shown. A–C, E, and F, values are mean ± S.E. Asterisks indicate statistically significant differences between WT and KO groups (p < 0.05 in at least n = 3 independent experiments).
Lack of Jak3 expression predisposes to colitis

WT controls. Further analysis at higher magnifications showed that the mucous layer above the epithelium was discontinuous (Fig. 2D, red arrows in ×100 and ×200), and the arrangement of cells from the base of the crypt to the surface was disturbed in KO mice (Fig. 2D, black arrow, ×400). In addition, both crypt lengths (Fig. 2D, ×200, yellow arrows) and widths (×400, blue lines) were decreased in KO mice. Further analysis showed that there was a 2-fold decrease in crypt length of KO mice (Fig. 2E).

Increased body weight is associated with IL-17a- and IL-6-mediated chronic low grade inflammation (30). Because the epithelial architectures were disturbed in untreated Jak3 KO mice, where these mice also showed increased body weight (Fig. 1A) compared with WT, we determined whether KO of Jak3 had an effect on basal inflammation in these mice. Indeed, the KO mice not only showed more than a 6-fold increase in colonic MPO activity, there was also a substantial increase in proinflammatory cytokines IL-6 and IL-17a in these tissues (Fig. 2, F–H). To determine whether the basal inflammation was restricted to the colon, we also determined mucosal structure, Jak3 expression, and MPO activities in small intestine (supplemental Fig. S1, A–C), which indicated that the perturbation of epithelial architecture and basal inflammation was not restricted to the colon only but extended to the small intestine as well. These results showed that KO of Jak3 led to disturbed colonic mucosal architecture that was associated with increased basal inflammation of the colon and small intestine. Although separate studies are underway (data not shown here) to determine the reason for weight gain in KO mice, this study focused on the mechanism of mucosal defects in these mice.

Mucosal Differentiations Were Affected in Jak3 KO Mice—Because Jak3 KO mice showed increased severity toward DSS-induced colitis and Jak3 is known to regulate differentiation of different cells (31, 32), we determined whether KO of Jak3 had effects on the differentiation of colonic mucosa. Our
results demonstrate that this was indeed the case where reduced expressions of differentiation markers were evident in the mucosal cells of Jak3 KO mice. These data show that Jak3 was not only expressed in colonic mucosae of mice (Fig. 3A), but the absence of Jak3 led to decreased expression of the differentiation markers for enterocytes, villin, and carbonic anhydrase (33, 34). Western analysis using colonic tissue lysates from these mice further confirmed the loss of Jak3 expression and reduced expression of villin and carbonic anhydrase in colon of KO mice (Fig. 3B). Because Jak3 KO mice showed a discontinuous mucous layer, we determined whether the number of goblet cells and the expression of secretory mucin (muc2) were affected in these mice. As shown in Fig. 3C, there was a nonsignificant decrease in the number of goblet cells per crypt in KO mice, but the surface localizations of these goblet cells in crypts were severely affected in colonic mucosae (Fig. 3D, top and middle panels) of these mice. Additionally, the expression of secretory mucin muc2 was also decreased in KO mice (Fig. 3D, bottom panel). Because decreased goblet cells and decreased muc2 expression are associated with increased incidence of ulcerative colitis in humans (3), these results establish a potential mechanistic link between goblet cell differentiation and increased severity toward DSS-induced colitis in Jak3 KO mice.

Jak3 Expression Facilitates Barrier Functions in Human IEC—Because loss of Jak3 expression led to a compromise in colonic differentiation and increased inflammatory state of colonic mucosa, by using an in vitro cell culture system we determined whether Jak3 expression was changed during the differentiation of IEC, and whether Jak3 expression influenced the epithelial barrier functions. Fig. 4A (left panel) shows that the expression of Jak3 increased with the differentiation of IEC
with a maximum expression at 2 weeks post-confluence. This was associated with increased expression of enterocytic differentiation markers villin and carbonic anhydrase. To determine whether Jak3 expression had a role in IEC differentiation, HT-29 cells were stably transfected with wild type HA-tagged Jak3. Jak3 expression promotes TEER. Control, HA-tagged Jak3-expressing (Jak3-HT-29) and doxycycline-regulated RFP-tagged Jak3-shRNA (shRNA-HT-29) expressing in Jak3-HT-29 cells were cultured in a 24-transwell plate to confluence, and TEER was measured. Mean values (n = 6 independent experiments) of TEER are shown. For Jak3 shRNA-HT-29, the expression of RFP-tagged Jak3-shRNA was induced by supplementing doxycycline in the growth media. Previously, we reported that this leads to knock down of Jak3 expression in HT-29 CL19A cells where treatment with doxycycline alone in untransduced cells had no effect on Jak3 expression (25). Sub and Conf, subconfluent and confluent, respectively, from WT and KO mice using methods described under “Experimental Procedures.” Lower panel in C and D show representative images (n = 3). B–D, values are means ± S.E. (n = 6). Asterisks indicate statistically significant differences (p < 0.05) from the control cells.

also determined the fecal α1-antitrypsin as a marker for PLE (36), using ELISA (Fig. 4D, upper panel) and dot blot (corresponding lower panel), both of which indicated an increased level in the fecal extracts of Jak3 KO mice. Together, these results demonstrate that Jak3 expression facilitates the expression of differentiation markers thereby promoting epithelial barrier functions in both differentiated IEC and in mice.

Jak3 Regulates β-Catenin Localization to AJ—Because Jak3 expression facilitated the epithelial barrier functions, we determined the effects of Jak3 knockdown on AJ in differentiated IEC. Fig. 5A shows that although expression of Jak3 was mostly restricted to apical surfaces in the confluent (bright field image in upper left panel and corresponding XZ images on the right panel) IEC, there was substantial increase in Jak3 expression at the basolateral surfaces of post-confluent differentiated IECs (bright field image in lower left panel and corresponding XZ images on right panels). For these experiments, A1 protein β-catenin was taken as control, the expression of which was also increased at the basolateral surfaces in the differentiated IEC (Fig. 5A, right, 2nd and 4th panels from the top). Because β-catenin localization to AJ is essential for the assembly of the junctions and maintenance of epithelial barrier functions (37), we determined whether the expression of Jak3 played a role in β-catenin localization to AJ. Fig. 5B, left panel, shows a contin-
Lack of Jak3 Expression Predisposes to Colitis

A

Confluent

4wks post-confluent

B

+ virus(-Dox) + virus(+Dox)

Green: β-catenin; Red: Jak3 shRNA

C

HT-29 CL19 A

150 kDa
IB:Jak3

100 kDa
IB:β-catenin

100 kDa
IB:pY20

100 kDa
IB:p(142)

100 kDa
IB:p(654)

β-catenin

100 kDa
IB:β-catenin

Input control

D

β-catenin

Lumen

WT

Jak3 KO

FIGURE 5. Jak3 facilitates AJ formation through interactions with β-catenin. A, Jak3 redistributes to basolateral surfaces in differentiated human IEC. Cellular redistribution of Jak3 was determined using IFM in confluent (nondifferentiated) and 2-week post-confluent (these had maximum expression of differentiation markers, Fig. 4A) HT-29 CL-19a cells. Bright field images (left panels) and corresponding XZ section (right panels) of Jak3 (green)-stained cells were taken to determine the basolateral redistribution using AJ protein β-catenin as a positive control. Representative images are shown (n = 5 experiments). B, Jak3 regulates β-catenin localization to AJ. AJ localization of β-catenin was determined in 2-week post-confluent HT-29 CL-19a cells transduced with lentiviruses mentioned in Fig. 4B and grown in the presence (+Dox) or absence (−Dox) of doxycycline, and IFM was performed using antibody for β-catenin. Representative images are shown (n = 6 experiments), where the green color indicates β-catenin and the red color confirms RFP-tagged Jak3-shRNA expression-mediated knockdown of Jak3 expression (25). Note that knockdown of Jak3 expression disrupts the AJ localization of β-catenin (white arrows) as denoted by punctate green staining in Jak3-shRNA-expressing (+Dox) cells. Bar 14 μm. C, Jak3 activation facilitates its interactions with tyrosine 654-phosphorylated pool of β-catenin. Left panel, co-IP followed by IB studies were done using cell lysates from HT-29 CL-19a cells and indicated antibodies. Representative blots are shown (n = 3 experiments). C, right panel, effect of inhibition of Jak3 on the interactions between Jak3 and β-catenin was studied using co-IP followed by IB studies from lysates of HT-29 CL-19A cells treated with Jak3 inhibitor WHI-P131 (25 μM). Previously, we reported that treatment with WHI-P131 leads to inhibition of Jak3 in HT-29 CL-19A cells (12, 13, 25). D, knock-out of Jak3 affects localization of β-catenin in colonic mucosa of mice. Localization of β-catenin was studied in colonic tissue sections from WT and KO mice using IFM as described in Fig. 3A. Representative images are shown (n = 5 experiments with three tissue sections per experiment). Profuse β-catenin staining in WT colon is evident in the crypt and villus regions (yellow and white arrows, respectively), which were absent in KO mice. Scale bar, 550 μm.

uous expression of β-catenin around the cellular periphery indicating an intact AJ in control differentiated IEC that was transduced with lentiviruses containing RFP-tagged Jak3 shRNA but was not supplemented with doxycycline in the growth media. However, when doxycycline was added to the growth media of these cells, it led to the expression of RFP-tagged Jak3 shRNA (indicated by red fluorescence, Fig. 5B, right panel) and substantial loss of β-catenin expression at AJ as indicated by relatively discontinuous and punctate staining for β-catenin at the cell periphery in these differentiated IEC. Doxycycline alone had no effect on the expression or localization of β-catenin, which showed similar results as the control (data not shown). Next, we determined whether Jak3 directly interacted with β-catenin and the conditions for their interactions. Fig. 5C (left panel, 1st and 2nd from the top) shows that Jak3 antibody co-immunoprecipitated β-catenin and vice versa from the cell lysates of differentiated IEC grown in the presence of serum. β-Catenin is known to be phosphorylated at tyrosine residues 142 and 645, where tyrosine 142-phosphorylated β-catenin is targeted to the nucleus to participate as a transcription factor for the expression of different genes (38). We determined whether Jak3-associated β-catenin was tyrosine-phosphorylated and whether the transcription factor pool (Tyr(P)-142) of β-catenin was present in this complex. Fig. 5C (left panel, 3rd from the top) shows that Jak3-associated β-catenin was tyrosine-phosphorylated but not at tyrosine 142, the transcription factor pool of β-catenin (left panel 4th from the top). Fig. 5C (5th panel from the top) shows that Jak3-associated β-catenin was phosphorylated mostly at tyrosine 654. We determined whether Jak3 activation was necessary for its interaction with β-catenin. Fig. 5C (top right panel) shows that β-catenin antibody immunoprecipitated β-catenin from the cell lysates of differentiated IEC that was treated with Jak3 inhibitor WHI-P131. However, Jak3-associated β-catenin was substantially reduced (Fig. 5C, compare with left panel, 2nd from the top) in the presence of the Jak3 inhibitor as indicated by Jak3 antibody co-immunoprecipitated β-catenin in the presence of WHI-P131. These results show that Jak3 activation was necessary for the interactions
between Jak3 and β-catenin where tyrosine residue 654 rather than 142 of β-catenin was phosphorylated through these interactions. Because Jak3 interacted with β-catenin and the expression of Jak3 was necessary for AJ localization of β-catenin, we determined the effect of loss of Jak3 on the localization of β-catenin in the colonic mucosa of mice. As shown in Fig. 5D, β-catenin was localized at the AJ toward the luminal surfaces of the differentiated colonic epithelial mucosa of WT mice (white arrow). In these mice, the undifferentiated crypt cells situated toward the bottom of the columnar crypt axis also showed β-catenin expression, which did not appear to be at the AJ (Fig. 5D, yellow arrow). In contrast, loss of Jak3 expression resulted in crypts that were not restricted to the bottom of the crypt axis but also migrated toward the luminal side of the mucosa (Fig. 5D, yellow arrow) and the columnar structures of the crypt axis were lost. Moreover, β-catenin was localized exclusively to these noncolumnar crypts only. Taken together, these results show that Jak3 not only interacted with β-catenin but also facilitated the localization of β-catenin to AJ in both differentiated IEC and in differentiated colonic mucosa of mice.

**DISCUSSION**

The gastrointestinal tract is a highly organized tissue that maintains homeostasis on three fronts as follows: (a) cells of microbiome situated over the mucosal surfaces; (b) the cells of mucosal surfaces itself, and (c) the cells of the immune system situated below the mucosal surface. Recently, we showed that Jak3 plays an essential role during mucosal wound repair and homeostasis (12, 14). Interestingly, although Jak3 interactions with cytoskeletal and adapter proteins were essential for mucosal wound repair function (12) and intestinal epithelial homeostasis, respectively (14), the in vivo significance of these functions was lacking. To achieve this, we first determined whether the absence of Jak3 expression influenced the severity of DSS-induced colitis in mice. Administration of synthetic DSS in drinking water leads to acute and chronic experimental ulcerative colitis in mice and is a good model to assess mucosal integrity (16). Our data suggested that although untreated Jak3 KO mice slightly gained weight over time compared with WT, treatment with DSS led to a substantial loss of body weight in KO mice that was associated with loss of mucosal integrity. These resulted in an increased severity of colitis in KO mice compared with WT. Although reduced expression of Jak3 has been reported in human ulcerative colitis patients (39), it was not known if the reduced expression of Jak3 was the cause for the effect of colitis. To find out if the absence of Jak3 was a reason for increased severity of colitis, we determined the basa(colonic inflammation in Jak3 KO mice. Our data indicated that absence of Jak3 expression resulted in shortened colon length, reduced colon to body weight ratio, and reduced cecum length in untreated mice. Although several studies indicated reduced colonic length post-DSS-induced colitis, it was not known if reduced colon length predisposes toward colitis (40, 41). We showed that Jak3-deficient mice had reduced colon length, and when these mice were subjected to DSS-induced colitis, they developed more severe colitis symptoms than their WT counterparts suggesting that Jak3 played a protective role during DSS-induced colitis (Fig. 1). Increased body weight and obesity are considered to be inflammatory predispositions, and these conditions predispose toward different inflammatory disorders, including inflammatory bowel disease. These in turn are mediated by increased expression of proinflammatory cytokines such as IL-6 and IL-17A (42, 43). Interestingly, our data suggested that although KO of Jak3 led to a marginal increase in body weight, the colonic levels of IL-6 and IL17A were substantially increased. This led to a low grade basal chronic inflammation as reflected by shortening of colon and cecum lengths with disturbed colonic and intestinal mucosal architecture and increased MPO activities (Fig. 2 and supplemental Fig. S1). Thus, it appears that KO of Jak3 was responsible for inflammatory predisposition of not only the colon but also the small intestine. Moreover, these conditions were aggravated when KO mice were subjected to colitis as reflected by increased severity of colonic inflammation during DSS-induced colitis.

To find out how the absence of Jak3 contributed to inflammation of the colon, we determined mucosal differentiation in the colon of Jak3 KO mice. Jak3 is widely expressed in different immune cells where, among other functions, it helps in their differentiation (44). Although Jak3 is also known to regulate differentiation of other cells types (31, 32), and our previous studies showed a role of Jak3 in mucosal wound repair and homeostasis (12–14), the role of Jak3 in mucosal differentiation was not known. Our data suggested that Jak3 not only promoted expression of colonic cytokerin markers in human IEC but the lack of Jak3 led to compromise in the differentiation of colonic mucosa as reflected by diminished expression of villin and carbonic anhydrase, the differentiation markers for enterocytic lineages (Figs. 3 and 4). Colonic mucosae of both human and mice are overlaid with a thick mucous layer that prevents the direct access of microbe to mucosal epithelia. The decreased mucous layer increases the severity of colitis in both humans and mice (45). Goblet cells are the major mucin-producing cells in colon where they produce secretory glycoproteins mucin (muc2), which is the major constituent of the protective mucus layer. Decreased muc2 expression is associated with the increased incidence of ulcerative colitis in humans (3, 46). In contrast, mice lacking intestinal mucin (muc2-2 KO) or mice with single missense mutations in the muc2 gene develop colitis with mucosal friability and spontaneous wound formation of the mucosa (47). Our data suggested that loss of Jak3 not only resulted in decreased surface localization of goblet cells toward the colonic lumen, it also affected the expression of secretory mucin, muc-2, that could be the reason for the discontinuous mucous layer and increased predisposition to colitis in mice (Fig. 3).

An intrinsic defect in the mucosal barrier has been implicated to be one of several factors that contribute to the exaggerated immune response to otherwise normal commensal microbiota. This leads to chronic inflammation during IBD (48). We showed that Jak3 promoted barrier functions in human IEC and its KO in mice predisposed toward colitis. Thus, it is safe to speculate that mucosal barrier in Jak3 KO mice was compromised as reflected by chronic low grade basal inflammation in colon, PLE symptoms, and increased severity during DSS-induced colitis. To understand mechanistically how Jak3 might be facilitating barrier functions, our data...
showed that Jak3 redistributed to basolateral surfaces in differentiated human IECs, Jak3 interacted with β-catenin, Jak3 activations were necessary for these interactions, and knockdown of Jak3 decreased TEER and AJ localizations of β-catenin. Expression of β-catenin at AJ is essential for the differentiation and barrier functions of colonic mucosa (49, 50). Altogether, these point to an essential role of Jak3 not only in mucosal differentiation but also in facilitating barrier functions through its interactions with β-catenin (Fig. 5). Although phosphorylation of tyrosine 142 of β-catenin facilitates its participation in transcription factor activity, phosphorylation of tyrosine 654 decreases intramolecular association between the C-terminal tail and the armadillo repeat domain, where armadillo repeat domain facilitates β-catenin interactions with E-cadherin (38, 51). Moreover, the phosphomimetic mutant Y654E of β-catenin that mimics constitutive phosphorylation at tyrosine 654 forms a functional cadherin-catenin complex to mediate strong cell adhesion (52). Our data suggest that phosphorylation of 654 and not of 142 was important for β-catenin interactions with Jak3 upon Jak3 activation. These indicate the physiological significance of these interactions where Jak3 activation led to β-catenin phosphorylation at Tyr-654, which promoted β-catenin interactions with E-cadherin, thereby facilitating AJ formation and enhancing the IEC barrier functions (Fig. 4). Because we showed that Jak3 was located at the apical surfaces in nondifferentiated/differentiated cells and previously we reported that the less phosphorylated form of Jak3 translocates to the nucleus in mucosal epithelial cells (14), it is possible that Jak3 interactions with β-catenin may facilitate nuclear translocation of these where they can influence the expression of differentiation markers through transcription factor activity in those cells that are not fully differentiated. Under in vivo conditions, because Jak3 played a key role in expression of differentiation markers, this role of Jak3 could be through its activation by different cytokine receptors at the apical surfaces in nondifferentiated/differentiated cells. However, Jak3 translocated to basolateral surfaces in fully differentiated cells where it facilitated cellular junction formation. Together, these data indicate that Jak3 expression was essential for differentiation, mucin expression, and barrier functions of colonic mucosa (Fig. 6). Additionally, these could have direct implications for patients with immunological disorders, including IBF where using immunosuppressive drugs having Jak3 inhibition activities may complicate the therapeutic outcome through compromised mucosal barrier functions (25, 53). Alternatively, using a delivery route with the least accumulation of Jak3 inhibitor at the intestinal mucosa may improve the outcome.

In summary, we showed that Jak3 played a critical role in the pathogenesis of colitis induced by DSS, where colonic expression of Jak3 was essential for a healthy mucosal barrier (Fig. 6), and knock-out of Jak3 resulted in a low grade chronic inflammation in colon and PLE symptoms, which predisposed the mice toward increased severity of colitis. In IEC, we demonstrated that Jak3 facilitated enhanced barrier functions through interactions and AJ localization of β-catenin. Thus, these results showed for the first time that Jak3 was essential for mucosal differentiation and barrier functions where it contributed to the expression of differentiation markers and reinforced barrier functions through its interactions with β-catenin.

Acknowledgment—We thank Dr. Sohel Quazi for technical help.

REFERENCES
1. Sancho, E., Batlle, E., and Clevers, H. (2003) Live and let die in the intestinal epithelium. Curr. Opin. Cell Biol. 15, 763–770
2. Dignass, A. U. (2001) Mechanisms and modulation of intestinal epithelial repair. Inflamm. Bowel Dis. 7, 68–77
3. Gersemann, M., Becker, S., Kübler, I., Koslowski, M., Wang, G., Herrlinger, K. R., Griger, J., Fritz, P., Fellermann, K., Schwab, M., Wehkamp, J., and Stange, E. F. (2009) Differences in goblet cell differentiation between Crohn’s disease and ulcerative colitis. Differentiation 77, 84–94
4. Pullan, R. D., Thomas, G. A., Rhodes, M., Newcombe, R. G., Williams, G. T., Allen, A., and Rhodes, J. (1994) Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 35, 353–359
5. Christodoulou, K., Wiskin, A. E., Gibson, J., Tapper, W., Willis, C., Afzal, N. A., Upstill-Goddard, R., Holloway, J. W., Simpson, M. A., Beattie, R. M., Collins, A., and Ennis, S. (2013) Next generation exome sequencing of paediatric inflammatory bowel disease patients identifies rare and novel variants in candidate genes. Gut 62, 977–984
6. Safford, M. G., Levenstein, M., Tsifrin, E., Amin, S., Hawkins, A. L., Griffen, C. A., Cavin, C. L., and Small, D. (1997) JAK3: expression and mapping to chromosome 19p12–13.1. Exp. Hematol. 25, 374–386
7. Takahashi, T., and Shirasawa, T. (1994) Molecular cloning of rat JAK3, a novel member of the JAK family of protein-tyrosine kinases. FEBS Lett. 342, 124–128
8. Murata, Y., Yamashita, A., Saito, T., Sugamura, K., and Hamuro, J. (2002) The conversion of redox status of peritoneal macrophages during pathological progression of spontaneous inflammatory bowel disease in Janus family tyrosine kinase 3−/− and IL-2 receptor γ−/− mice. Int. Immunol. 14, 627–636
9. Cornejo, M. G., Boggan, T. J., and Mercher, T. (2009) Jak3: a two-faced player in hematological disorders. Int. J. Biochem. Cell Biol. 41, 2356–2379
cinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167, 969–980
11. Mishra, J., Drummond, J., Quazi, S. H., Karaniki, S. S., Shaw, J. I., Chen, B., and Kumar, N. (2013) Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit. Rev. Oncol. Hematol. 86, 232–250
12. Kumar, N., Mishra, J., Narang, V. S., and Waters, C. M. (2007) Janus kinase 3 regulates interleukin-2-induced mucosal wound repair through tyrosine phosphorylation of villin. J. Biol. Chem. 282, 30341–30345
13. Mishra, J., Karaniki, S. S., and Kumar, N. (2012) Identification of molecular switch regulating interactions of Janus kinase 3 with cytoskeletal proteins. J. Biol. Chem. 287, 41386–41431
14. Mishra, J., Waters, C. M., and Kumar, N. (2012) Molecular mechanism of interleukin-2-induced mucosal homeostasis. Am. J. Physiol. Cell Physiol. 302, C735–C747
15. Cormet-Boyaka, E., Di, A., Chang, S. Y., Naren, A. P., Tousson, A., Nelson, D. J., and Kirk, K. L. (2002) CFTR chloride channels are regulated by a SNAP-23/ syntaxin 1A complex. Proc. Natl. Acad. Sci. U.S.A. 99, 12477–12482
16. Okayasu, I., Hatakeyama, S., Yamada, M., Obhuka, T., Inagaki, Y., and Nakaya, R. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694–702
17. Mashimo, H., Wu, D. C., Podolsky, D. K., and Fishman, M. C. (1996) Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274, 262–265
18. Cooper, H. S., Murthy, S. N., Shah, R. S., and Sedergran, D. J. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238–249
19. Xu, Y., Hunt, N. H., and Bao, S. (2008) The role of granulocyte macrophage-colony-stimulating factor in acute intestinal inflammation. Cell Res. 18, 1220–1229
20. Mackay, F., Browning, J. L., Lawton, P., Shah, S. A., Nelson, D. J., and Kirk, K. L. (2002) CFTR chloride channels are regulated by a SNAP-23/syntaxin 1A complex. Proc. Natl. Acad. Sci. U.S.A. 99, 12477–12482
21. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A., and Narumiya, S. (2002) The prostaglandin receptor EP4 suppresses colitis, mental murine models of colitis. J. Biol. Chem. 2718–2729
22. Alexander, J. S. (2010) Angiopoietin-2 in experimental colitis. Gastroenterology 139, 1029–1039
23. Dorofeyev, A. E., Vasilenko, I. V., Rassokhina, O. A., and Kondratiuk, R. B. (2000) Immunoglobulin leakiness in scid mice with CD4+ T-cell-induced chronic colitis. Clin. Immunol. 96, 222–229
24. You, H., Padmashali, R. M., Ranganathan, A., Lei, P., Giriun, N., Davis, R. J., and Andreadis, S. T. (2013) JNK regulates compliance-induced adhesions junctions formation in epithelial cells and tissues. J. Cell Sci. 126, 2718–2729
25. Piedra, J., Miravit, S., Cañajo, J., Palmer, H. G., Heisterkamp, N., García de Herreeros, A., and Duñach, M. (2003) p120 Catenin-associated Fer and Fyn tyrosine kinases regulate β-catenin Tyr-142 phosphorylation and β-catenin-α-catenin interaction. Mol. Cell. Biol. 23, 2287–2297
26. Sai, D. S., Wu, G., Zou, Y., Feng, Y. L., Liu, H. B., Fung, J. S., Chi, H. G., Lv, R. X., and Zheng, X. B. (2013) Balance of CD8+ CD28+ /CD8+ CD28− T lymphocytes is vital for patients with ulcerative colitis. Dig. Dis. Sci. 58, 88–96
27. Assi, K., Mills, J., Owen, D., Ong, C., St Arnaud, R., Dedhar, S., and Salh, B. (2008) Integrin-linked kinase regulates cell proliferation and tumour growth in murine colitis-associated carcinogenesis. Gut 57, 931–940
28. Banner, K. H., Cattaneo, C., Le Net, J. L., Popovic, A., Collins, D., and Galle, J. D. (2004) Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br. J. Pharmacol. 143, 590–598
29. Hass, D. J., Brensinger, C. M., Lewis, J. D., and Lichtenstein, G. R. (2006) The impact of increased body mass index on the clinical course of Crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 482–488
30. Züniga, L. A., Shen, W. J., Joyce-Shaik, B., Pyatnova, E. A., Richards, A. G., Thom, C., Andrade, S. M., Cua, D. J., Kraemmer, F. B., and Butcher, E. C. (2010) IL-17 regulates adipsinogen, glucose homeostasis, and obesity. J. Clin. Investig. 118, 169–178
31. Shi, M., Lin, T. H., Appell, K. C., and Berg, L. J. (2008) Janus-kinase-3-deleted signal induction: impact of fucosyltransferase VII and trefoil factor 3. Am. J. Physiol. Cell Physiol. 299, G43–G53
32. Johannsen, M. E., Gustafsson, J. K., Holmén-Larsson, J., Jabbar, K. S., Xia, L., Xu, H., Ghishan, F. K., Cavallaro, F. A., Gewirtz, A. T., Sjövall, H., and Hansson, G. C. (2013) Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 62, G43–G53
33. Beck, P. L., Ibara, E., Hirota, S. A., MacDonald, J. A., Meng, D., Nanthaku-
Lack of Jak3 Expression Predisposes to Colitis

Kosa, P., Szabo, R., Molinolo, A. A., and Bugge, T. H. (2012) Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. *Oncogene* **31**, 3679–3695

Joo, M., Shahsafaei, A., and Odze, R. D. (2009) Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/β-catenin/Tcf pathway. *Hum. Pathol.* **40**, 872–880

Mariadason, J. M., Bordonaro, M., Aslam, F., Shi, L., Kuraguchi, M., Velcich, A., and Augenlicht, L. H. (2001) Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. *Cancer Res.* **61**, 3465–3471

Piedra, J., Martinez, D., Castano, J., Miravet, S., Dunach, M., and de Herreros, A. G. (2001) Regulation of β-catenin structure and activity by tyrosine phosphorylation. *J. Biol. Chem.* **276**, 20436–20443

Tominaga, J., Fukunaga, Y., Abelardo, E., and Nagafuchi, A. (2008) Defining the function of β-catenin tyrosine phosphorylation in cadherin-mediated cell-cell adhesion. *Genes Cells* **13**, 67–77

Vuitton, L., Koch, S., and Peyrin-Biroulet, L. (2013) Janus kinase inhibition with Tofacitinib: Changing the face of inflammatory bowel disease treatment. *Curr. Drug Targets*, in press

ulcerative colitis. *PLoS Med.* **5**, e54

48. Kosa, P., Szabo, R., Molinolo, A. A., and Bugge, T. H. (2012) Suppression of Tumorigenicity-14, encoding matriptase, is a critical suppressor of colitis and colitis-associated colon carcinogenesis. *Oncogene* **31**, 3679–3695

49. Joo, M., Shahsafaei, A., and Odze, R. D. (2009) Paneth cell differentiation in colonic epithelial neoplasms: evidence for the role of the Apc/β-catenin/Tcf pathway. *Hum. Pathol.* **40**, 872–880

50. Mariadason, J. M., Bordonaro, M., Aslam, F., Shi, L., Kuraguchi, M., Velcich, A., and Augenlicht, L. H. (2001) Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. *Cancer Res.* **61**, 3465–3471

51. Piedra, J., Martinez, D., Castano, J., Miravet, S., Dunach, M., and de Herreros, A. G. (2001) Regulation of β-catenin structure and activity by tyrosine phosphorylation. *J. Biol. Chem.* **276**, 20436–20443

52. Tominaga, J., Fukunaga, Y., Abelardo, E., and Nagafuchi, A. (2008) Defining the function of β-catenin tyrosine phosphorylation in cadherin-mediated cell-cell adhesion. *Genes Cells* **13**, 67–77

53. Vuitton, L., Koch, S., and Peyrin-Biroulet, L. (2013) Janus kinase inhibition with Tofacitinib: Changing the face of inflammatory bowel disease treatment. *Curr. Drug Targets*, in press